Intramyocellular Triglyceride Content During the Early Course of Type 1 and Type 2 Diabetes
Diabetes · 2023
DOI: 10.2337/db23-0353 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, 2023. Verfasst von Martin Schön und 18 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Clinical Diabetology, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University Düsseldorf, Düsseldorf,…. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Insulin Resistance, Cardiovascular Diseases, Diabetes Mellitus, Type 1. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: EUREKA Eurostars-2, INTERCEPT-T2D consortium, German Federal Ministry of Health.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Intramyocellular lipid content (IMCL) is elevated in insulin-resistant humans, but it changes over time, and relationships with comorbidities remain unclear. We examined IMCL during the initial course of diabetes and its associations with complications. Participants of the German Diabetes Study (GDS) with recent-onset type 1 (n = 132) or type 2 diabetes (n = 139) and glucose-tolerant control subjects (n = 128) underwent 1H-MRS to measure IMCL and muscle volume, whole-body insulin sensitivity (hyperinsulinemic-euglycemic clamps; M-value), and cycling spiroergometry (VO2max). Subgroups underwent the same measurements after 5 years. At baseline, IMCL was ∼30% higher in type 2 diabetes than in other groups independently of age, sex, BMI, and muscle volume. In type 2 diabetes, the M-value was ∼36% and ∼62% lower compared with type 1 diabetes and control subjects, respectively. After 5 years, the M-value decreased by ∼29% in type 1 and ∼13% in type 2 diabetes, whereas IMCL remained unchanged. The correlation between IMCL and M-value in type 2 diabetes at baseline was modulated by VO2max. IMCL also associated with microalbuminuria, the Framingham risk score for cardiovascular disease, and cardiac autonomic neuropathy. Changes in IMCL within 5 years after diagnosis do not mirror the progression of insulin resistance in type 2 diabetes but associate with early diabetes-related complications. Article Highlights Intramyocellular lipid content (IMCL) can be elevated in insulin-resistant humans, but its dynamics and association with comorbidities remain unclear. Independently of age, sex, body mass, and skeletal muscle volume, IMCL is higher in recent-onset type 2, but not type 1 diabetes, and remains unchanged within 5 years, despite worsening insulin resistance. A degree of physical fitness modulates the association between IMCL and insulin sensitivity in type 2 diabetes. Whereas higher IMCL associates with lower insulin sensitivity in people with lower physical fitness, there is no association between IMCL and insulin sensitivity in those with higher degree of physical fitness. IMCL associates with progression of microalbuminuria, cardiovascular disease risk, and cardiac autonomic neuropathy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Institute for Clinical Diabetology, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
- German Center for Diabetes Research, Partner Düsseldorf, München-Neuherberg, Germany.
- Department of Endocrinology and Diabetology, Medical Faculty and University Hospital Düsseldorf, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
- Institute for Biometrics and Epidemiology, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
- Department of Cardiology, Pulmonology and Vascular Medicine, Medical Faculty and University Hospital Düsseldorf, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
- Cardiovascular Research Institute Düsseldorf, Medical Faculty and University Hospital Düsseldorf, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
ORCID-Profile: Alexander Strom, Gidon J Bönhof, Michael Roden
Förderung
- EUREKA Eurostars-2
- INTERCEPT-T2D consortium
- German Federal Ministry of Health
- Schmutzler Stiftung
- German Science Foundation
- German Federal Ministry of Education and Research
- Ministry of Culture and Science of the State Northrhine Westphalia
Zitieren
APA
Schön, M., Zaharia, O. P., Strassburger, K., Kupriyanova, Y., Bódis, K., Heilmann, G., Strom, A., Bönhof, G. J., Michelotti, F., Yurchenko, I., Möser, C., Huttasch, M., Bombrich, M., Kelm, M., Burkart, V., Schrauwen-Hinderling, V. B., Wagner, R., Roden, M., & GDS Group (2023). Intramyocellular Triglyceride Content During the Early Course of Type 1 and Type 2 Diabetes. Diabetes. https://doi.org/10.2337/db23-0353
Vancouver
Schön M, Zaharia OP, Strassburger K, Kupriyanova Y, Bódis K, Heilmann G, et al. Intramyocellular Triglyceride Content During the Early Course of Type 1 and Type 2 Diabetes. Diabetes. 2023. doi:10.2337/db23-0353
BibTeX
@article{Schn2023,
author = {Schön, Martin and Zaharia, Oana P and Strassburger, Klaus and Kupriyanova, Yuliya and Bódis, Kálmán and Heilmann, Geronimo and Strom, Alexander and Bönhof, Gidon J and Michelotti, Filippo and Yurchenko, Iryna and Möser, Clara and Huttasch, Maximilian and Bombrich, Maria and Kelm, Malte and Burkart, Volker and Schrauwen-Hinderling, Vera B and Wagner, Robert and Roden, Michael and GDS Group, GDS Group},
title = {Intramyocellular Triglyceride Content During the Early Course of Type 1 and Type 2 Diabetes},
journal = {Diabetes},
year = {2023},
doi = {10.2337/db23-0353}
}
EUVIMED